Log in to search using one of your social media accounts:

 

Beyond APHINITY: What Now After Pivotal Breast Cancer Trial? Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

' Soft' Chemo Plus Targeted Therapy Works in HER2 Breast Cancer (CME/CE)
(MedPage Today) -- Combo increased PFS in older patients and had an acceptable safety profile (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 9, 2018 Category: OBGYN Source Type: news

Soft chemotherapy is very effective in older patients when added to targeted treatment in an aggressive breast cancer subtype
(European Organisation for Research and Treatment of Cancer) A trial published todayin The Lancet Oncology, shows that, in older patients with HER2 positive metastatic breast cancer (an aggressive breast cancer subtype where the cancer has spread to other parts of the body), a combination of a 'soft' chemotherapy with antiHER2 therapy is highly active and has low toxicity, important in a frail population. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 9, 2018 Category: International Medicine & Public Health Source Type: news

Trastuzumab Biosimilar Equivalent in Early HER2+ Breast CA Tx (CME/CE)
(MedPage Today) -- Ratio of breast pathologic complete response rate 10% higher with SB3 (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 7, 2018 Category: Hematology Source Type: news

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors
Mutations mimicking growth factor–induced proliferation and motility characterize aggressive subtypes of mammary tumors. To unravel currently unknown players in these processes, we performed phosphoproteomic analysis on untransformed mammary epithelial cells (MCF10A) that were stimulated in culture with epidermal growth factor (EGF). We identified ladinin-1 (LAD1), a largely uncharacterized protein to date, as a phosphorylation-regulated mediator of the EGF-to-ERK pathway. Further experiments revealed that LAD1 mediated the proliferation and migration of mammary cells. LAD1 was transcriptionally induced, phosphorylat...
Source: Signal Transduction Knowledge Environment - January 30, 2018 Category: Science Authors: Roth, L., Srivastava, S., Lindzen, M., Sas-Chen, A., Sheffer, M., Lauriola, M., Enuka, Y., Noronha, A., Mancini, M., Lavi, S., Tarcic, G., Pines, G., Nevo, N., Heyman, O., Ziv, T., Rueda, O. M., Gnocchi, D., Pikarski, E., Admon, A., Caldas, C., Yarden, Y. Tags: STKE Research Articles Source Type: news

Two Agents Offer Similar pCR Rates in ETNA Breast Cancer Trial (CME/CE)
(MedPage Today) -- Tumor subtype most significant factor for response among ERBB/HER2-negative patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 15, 2018 Category: Hematology Source Type: news

UC researchers find protein that mediates formation of HER2-driven breast cancer
(University of Cincinnati Academic Health Center) Researchers at the University of Cincinnati College of Medicine have identified for the first time that the estrogen receptor-binding protein MED1 is a critical mediator of HER2-driven breast cancer, identifying it as a potential therapeutic target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 9, 2018 Category: Cancer & Oncology Source Type: news

Novartis Kisqali ® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. (Source: World Pharma News)
Source: World Pharma News - January 3, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Trastuzumab: No negative impact on cardiac function
(NRG Oncology) Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer who survive without cancer recurrence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 3, 2018 Category: International Medicine & Public Health Source Type: news

Will Immunotherapy Be a PANACEA for Breast Cancer? Will Immunotherapy Be a PANACEA for Breast Cancer?
Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Ganetespib, Paclitaxel, Trastuzumab for HER2+ Breast Cancer Ganetespib, Paclitaxel, Trastuzumab for HER2+ Breast Cancer
Early research finds that ganetespib added to paclitaxel and trastuzumab shows promise for heavily pretreated patients with HER2+ breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Mylan breast cancer drug approved in Brazil
Mylan NV on Friday said it had received the green light in Brazil for a treatment for breast cancer that it developed with a partner in the country. Biocon LTD (BSE: BIOCON) and Mylan (Nasdaq: MYL) co-developed biosimilar Trastuzumab, which treats overexpressing HER2-positive metastatic breast cancer, HER2-positive early stage breast cancer and HER2-positive advanced gastric cancer. It will be sold in Brazil in Brazil as Zedora by Libbs Farmac eutica. "The approval of Zedora, Brazil's first Trastuzumab… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 29, 2017 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Triple Therapy Improves PFS in Certain Breast Ca Patients (CME/CE)
(MedPage Today) -- Dual HER2 blockade combined with aromatase inhibitor shows benefit (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 28, 2017 Category: Hematology Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - December 21, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - December 21, 2017 Category: Pharmaceuticals Source Type: news

Lapatinib With Foretinib in HER2+ Metastatic Breast Cancer Lapatinib With Foretinib in HER2+ Metastatic Breast Cancer
Early research finds limited activity with the combination of lapatinib and foretinib for advanced HER2+ breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Aspirin, NSAIDs and Prospective Risk of HER2+ Breast Cancer Aspirin, NSAIDs and Prospective Risk of HER2+ Breast Cancer
Does aspirin or ibuprofen reduce risk of HER2+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC
Is the combination of everolimus, trastuzumab, and paclitaxel as safe in Asian patients as it is in the overall population?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at the University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 8, 2017 Category: Cancer & Oncology Source Type: news

Ribociclib Effective in Younger Breast Cancer Patients Too Ribociclib Effective in Younger Breast Cancer Patients Too
In premenopausal women with HR-positive, HER2-negative advanced breast cancer, the CDK4/6 inhibitor plus endocrine therapy dramatically improves progression-free survival compared with endocrine therapy alone.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biological factors don't fully explain racial disparities for breast cancer type
(UNC Lineberger Comprehensive Cancer Center) The biological features of patients' tumors partially explained a racial disparity for women with hormone receptor-positive, HER2-negative breast cancer, but UNC Lineberger Comprehensive Cancer Center researchers said it didn't explain it completely. The preliminary findings were reported at the 2017 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2017 Category: International Medicine & Public Health Source Type: news

SABCS: Ribociclib Ups PFS in HR + HER2 − Advanced Breast Cancer
Significant improvement in progression - free survival for pre - and perimenopausal women (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 7, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Conference News, Source Type: news

Trastuzumab No Benefit In Low-HER2 Breast Cancer (CME/CE)
(MedPage Today) -- New findings should ditch use of drug for women not clearly HER2-positive (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - December 6, 2017 Category: Surgery Source Type: news

No Trastuzumab Benefit in HER2-Low Breast Cancer After All No Trastuzumab Benefit in HER2-Low Breast Cancer After All
Despite previous analyses suggesting that adding trastuzumab to adjuvant chemotherapy may benefit patients with low HER2 expression, a new large trial shows no impact on outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ
Malignant tumors reprogram cellular metabolism to support cancer cell proliferation and survival. Although most cancers depend on a high rate of aerobic glycolysis, many cancer cells also display addiction to glutamine. Glutamine transporters and glutaminase activity are critical for glutamine metabolism in tumor cells. We found that the receptor tyrosine kinase EphA2 activated the TEAD family transcriptional coactivators YAP and TAZ (YAP/TAZ), likely in a ligand-independent manner, to promote glutamine metabolism in cells and mouse models of HER2-positive breast cancer. Overexpression of EphA2 induced the nuclear accumula...
Source: Signal Transduction Knowledge Environment - December 5, 2017 Category: Science Authors: Edwards, D. N., Ngwa, V. M., Wang, S., Shiuan, E., Brantley-Sieders, D. M., Kim, L. C., Reynolds, A. B., Chen, J. Tags: STKE Research Articles Source Type: news

FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer
The agency has approved the first biosimilar that corresponds to Herceptin for use in HER2+ breast and metastatic stomach cancer.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Trastuzumab Biosimilar
(MedPage Today) -- Includes HER2-positive breast, stomach cancer (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 1, 2017 Category: Gastroenterology Source Type: news

FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Ogivri, a biosimilar to the cancer drug Herceptin, is approved for HER2+ breast cancer and metastatic stomach cancers SILVER SPRING, Md., Dec. 1, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved Ogiv... Biopharmaceuticals, Oncology, FDA Mylan, Ogivri, trastuzumab-dkst, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 1, 2017 Category: Pharmaceuticals Source Type: news

FDA approves first biosimilar for the treatment of certain breast and stomach cancers
The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer. (Source: World Pharma News)
Source: World Pharma News - December 1, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

What's Hot at SABCS 2017? What's Hot at SABCS 2017?
Can the duration of adjuvant therapy in breast cancer be reduced? Is trastuzumab effective in HER2-negative tumors? These are among the hot topics that will be discussed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neratinib: Extended Adjuvant Therapy, But When to Prescribe? Neratinib: Extended Adjuvant Therapy, But When to Prescribe?
The ExteNET study led to the approval of neratinib for extended adjuvant treatment of early-stage HER2+ breast cancer. But when should it be prescribed?Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Negligible Benefit Of Nerlynx, A New Breast Cancer Drug, Calls For Caution
The question for patients with early-stage HER2+ breast cancer is if it ’s worth taking a treatment (Nerlynx) that lowers the risk of distant recurrence by less than 2% at 5 years, and which has not yet been studied over the long term. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2017 Category: Pharmaceuticals Authors: Elaine Schattner, Contributor Tags: NASDAQ:PBYI VTX:ROG Source Type: news

More than 1,300 women to get breakthrough cancer drug
The treatment – for the aggressive HER2+ form of the disease – extends life for women dying with breast cancer by an average 56 months, 16 months more than the next best treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - November 10, 2017 Category: Consumer Health News Source Type: news

FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer
Verzenio ™ (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - October 12, 2017 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for metastatic breast cancers
The U.S. Food and Drug Administration Thursday approved Verzenio to treat adult patients with HR positive and HER2 negative metastatic breast cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 29, 2017 Category: Consumer Health News Source Type: news

Roche's Perjeta regimen gets FDA priority review in breast cancer
ZURICH (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants Priority Review for Roche ’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC). The FDA is exp ected to make a decision on approval by 28 January 2018. (Source: Roche Media News)
Source: Roche Media News - September 29, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review for Roche ’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC). The FDA is exp ected to make a decision on approval by 28 January 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - September 29, 2017 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for certain advanced or metastatic breast cancers
The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient ’s hormones (endocrine therapy). (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2017 Category: American Health Source Type: news

FDA Approves Verzeniov (abemaciclib) for Certain Advanced or Metastatic Breast Cancers
September 28, 2017 -- The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Verzenio (abemaciclib) for Certain Advanced or Metastatic Breast Cancers
September 28, 2017 -- The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

US Oncology Research Plays an Important Role in the Clinical Development for NERLYNX ™ (Neratinib) Tablets
The Woodlands, Texas (September 12, 2017) — Early-stage breast cancer patients with HER2-positive tumors now have a promising new anti-HER2 treatment option in the extended adjuvant setting, thanks in large part to the efforts and expertise of US Oncology Research and McKesson Specialty Health. US O... (Source: McKesson News)
Source: McKesson News - September 12, 2017 Category: Information Technology Source Type: news

Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer
Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients Largest immuno-oncolytic virus safety database reported to-date demonstrates REOLYSIN® is s... Biopharmaceuticals, Oncology Oncolytics Biotech, REOLYSIN, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 11, 2017 Category: Pharmaceuticals Source Type: news

Taselisib Added to Letrozole Boosts Response in Breast Cancer Taselisib Added to Letrozole Boosts Response in Breast Cancer
Taselisib, a PIK3CA targeted agent, in combination with letrozole significantly increased overall response rates in postmenopausal women with ER+/HER2- stage I-III operable breast cancer. ORRs were more robust in patients with PIK3CA mutations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity THOUSAND OAKS, Calif. and DUBLIN, Sept. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a Herceptin® (trastuzumab) biosimilar, compared with the originator product in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. Results from the neoadjuvant efficacy phase of the study, including pathologic complete response ass...
Source: Amgen News Release - September 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

LORELEI: Taselisib boosts breast tumor shrinkage
(European Society for Medical Oncology) Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news